| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:7923161 | IVR | 70 mg/L | - | No significant effects observed | - |
| IVR | 220 mg/L | - | No significant effects observed | - | |
| IVR | 7000 mg/L | 7000 mg/L | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 7000 mg/L | 7000 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 7000 mg/L | 7000 mg/L | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 7000 mg/L | 7000 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 7000 mg/L | 7000 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 7000 mg/L | 7000 mg/L | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 7000 mg/L | 7000 mg/L | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 2200 mg/L | 2200 mg/L | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 2200 mg/L | 2200 mg/L | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 2200 mg/L | 2200 mg/L | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 2200 mg/L | 2200 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 2200 mg/L | 2200 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 2200 mg/L | 2200 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 2200 mg/L | 2200 mg/L | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 700 mg/L | 700 mg/L | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 700 mg/L | 700 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 700 mg/L | 700 mg/L | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 700 mg/L | 700 mg/L | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 700 mg/L | 700 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 700 mg/L | 700 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 700 mg/L | 700 mg/L | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.